MedTrace Logo

Identification and Description of Patients With High-risk Non Metastatic RCC

NCT07753343 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 6109

Last updated 2026-08-07

No results posted yet for this study

Summary

Renal cell carcinoma (RCC) is the 14th most common cancer worldwide. Surgery is the standard of care for localized RCC, however, the risk of recurrence varies widely among patients. Adjuvant pembrolizumab has been shown to improve outcomes after nephrectomy but is associated with substantial toxicity and high costs. This study uses real-world data from the French UroCCR-Chain registry to characterize the natural history, management, and outcomes of non-metastatic RCC in France, with the aim of informing adjuvant treatment decisions

Conditions

Interventions

OTHER

Cohort 1

Overall RCC Population

OTHER

Cohort 2

Non clear RCC population

OTHER

Cohort 3

Clear RCC population stratified by eligibility based on the Keynote-564 study criteria

Sponsors & Collaborators

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • Jean-Christophe BERNHARD, Pr · University Hospital, Bordeaux

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-17
Primary Completion
2028-04-17
Completion
2028-04-17

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07753343 on ClinicalTrials.gov